)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Arbutus Biopharma (ABUS) investor relations material
Arbutus Biopharma Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary13 Nov, 2025
Executive summary
Focused on developing imdusiran (AB-729) and AB-101 for chronic hepatitis B, with a streamlined organization and reduced workforce to prioritize clinical development and cost management.
Ended strategic partnership with Qilu, regaining global rights to imdusiran and recognizing all previously deferred revenue.
Imdusiran (AB-729) clinical data showed 46% of Phase 2a patients met criteria to discontinue all treatment, with 94% of long-term follow-up patients remaining off all treatment for up to 2+ years.
Ongoing patent litigation against Moderna and Pfizer/BioNTech for use of LNP technology, with favorable claim construction rulings and trial dates set for 2026 and 2027.
Launched a new Scientific Advisory Board to guide clinical strategy.
Financial highlights
Total revenue for Q3 2025 was $0.5M, down from $1.3M in Q3 2024; nine-month revenue rose to $13.0M from $4.6M year-over-year, mainly due to $9.6M deferred revenue recognized after Qilu agreement termination.
Net loss for Q3 2025 was $7.7M ($0.04 per share), improved from $19.7M ($0.10 per share) in Q3 2024; nine-month net loss was $29.7M, down from $57.4M year-over-year.
Operating expenses for Q3 2025 were $9.2M, down from $22.8M in Q3 2024; nine-month operating expenses were $45.9M, down from $67.0M year-over-year.
Research and development expenses decreased to $5.8M from $14.3M year-over-year, and general and administrative expenses fell to $3.0M from $4.5M.
Cash, cash equivalents, and marketable securities totaled $93.7M as of September 30, 2025, with no outstanding debt.
Outlook and guidance
Expects significantly reduced net cash burn in 2025 compared to 2024 due to organizational changes and cost management.
All remaining restructuring-related payments are expected to be completed by Q1 2026.
Believes current cash resources are sufficient to fund operations for at least the next 12 months.
The company remains dedicated to accelerating the development and potential approval of imdusiran.
Impact of favorable Pfizer claim ruling
Imdusiran long-term off-treatment durability impact
Estimate cash runway given burn and cost cuts
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Arbutus Biopharma earnings date
Q4 20255 Mar, 2026
Next Arbutus Biopharma earnings date
Q4 20255 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Arbutus Biopharma Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapies for viral diseases. The company utilizes its expertise in RNA interference (RNAi) technology and small molecule development to address diseases such as chronic hepatitis B. Arbutus conducts research and development to advance its proprietary drug candidates and explore combination treatment approaches. The company is headquartered in Warminster, Pennsylvania, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage